Skip to main content
Prescription drug costs image by TaxRebate.org.uk via Flickr

Public Pharmaceuticals As An Antidote to Big Pharma’s Market Failure

Dana Brown

Dana Brown

Director of the Next System Project more

Health & Wellbeing

Drug-resistant “superbugs” are predicted to kill more people per year than cancer by 2050. It’s a problem that’s increasingly seen as a threat to national security, with potential consequences for trade, global development and even counterterrorism.

It’s also a problem that the pharmaceutical industry is unwilling to make the investments to address, because, they say, there is no market incentive to do so.

In an article today for The American Prospect, I argue that given this “bad case of market-incentive syndrome, it is time to consider the establishment of public pharmaceutical companies as an antidote.”

The federal government has already tried all of the traditional forms of persuasion to entice pharmaceutical companies to pour more research and development money, the article says, but the strategy has failed. The crux of the issue: “the industry’s increasingly financialized business model, which puts profits over people.”

Ensuring that the public has access to next-generation antibiotics and other life-saving drugs would require severing the tie between R&D costs and sales volume, what’s referred to in the industry as “delinkage.” “The ultimate form of delinkage would be to take the development and production of medicines like these into public hands and out of the market entirely,” I write. “What’s more, Americans across the political spectrum already support the idea of a public option in pharmaceuticals.”

You can read the full article at The American Prospect.

Dana Brown

Dana Brown

Director of the Next System Project more

More related work

A blister pack of medicine in pill form

Commitments to public pharmaceutical production in the Democratic primary

Our report Medicine For All: The Case for a Public Option in the Pharmaceutical Industry  argues that truly making pharmaceuticals accessible and affordable for all Americans will require public ownership of pharmaceutical production read more
A pipette being dipped into an array of testtubes

A National Pharmaceutical Research and Development Institute

To promote the execution of pharmaceutical R&D in the public interest, the US should establish a national pharmaceutical R&D institute for full-cycle drug development, which will help promote long-term access to medicines, reignite innovation, and ensure prioritization of public health needs. read more
Lower drug prices now

Lower drug costs now through a pharmaceutical public option

House Speaker Nancy Pelosi on September 19 released the “Lower Drug Costs Now Act” (H.R. 3), which would institute a series of measure read more